

REMARKS

Upon entry of the amendment, claims 1, 8-10, 14-20, 25, 29, 31, 34, 41-43, 47-53, and 58 will be pending. The specification has been amended to insert a priority statement, make reference to the sequence listing that was filed with the parent application, correct obvious typographical errors, and to update references to filed patent applications that are now published.

The Applicants submit that these amendments do not constitute new matter.

FEES

It is believed that no fee is due with this amendment. However, if a fee is due, the Commissioner is hereby authorized to charge the Deposit Account 50-0252 referencing case number ISIS-0543US.

CONCLUSIONS

In view of these amendments and remarks, the Applicants believe that the case is now in proper form for examination. A prompt office action on the merits of the case is requested.

Date: Feb 14, 2006

Respectfully submitted,



Colleen J McKiernan, Ph.D.

Agent for Applicant

Reg. No. 48,570

ISIS PHARMACEUTICALS, INC.
1896 Rutherford Road
Carlsbad, CA 92003

Phone: 760-603-2722

Fax: 760-603-3820